Utah Medical Products
UTMD
81 hedge funds and large institutions have $256M invested in Utah Medical Products in 2018 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 25 increasing their positions, 28 reducing their positions, and 9 closing their positions.
75% more capital inflows, than outflows
Capital inflows: $18.8M | Capital outflows: $10.8M
33% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 9
4% more funds holding
Funds holding: 78 → 81 (+3)
2.19% more ownership
Funds ownership: 67.14% → 69.32% (+2.2%)
11% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lazard Asset Management
New York
|
+$10.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.72M |
| 3 |
Ancora Advisors
Cleveland,
Ohio
|
+$823K |
| 4 |
Raymond James & Associates
St Petersburg,
Florida
|
+$767K |
| 5 |
Russell Investments Group
London,
United Kingdom
|
+$656K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.15M |
| 2 |
Morgan Dempsey Capital Management
Menomonee Falls,
Wisconsin
|
-$1.19M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$941K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$573K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$551K |
UTMD Hedge Fund Activity: Q1 2018 in Review
81 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Utah Medical Products (UTMD) for Q1 2018, worth a combined $256M — up 26% from $203M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new UTMD positions and 9 closed out — a net gain of 3 holders — while 25 added to existing stakes and 28 trimmed.
The largest buyer was Lazard Asset Management, opening a new position worth an estimated $10.1M. The largest seller was Vanguard Group, cutting an estimated $3.15M.
- 81 institutional investors held Utah Medical Products (UTMD) as of Q1 2018, up from 78 in Q4 2017.
- Funds reported $256M of Utah Medical Products stock for Q1 2018, up 26% quarter-over-quarter.
- 12 funds opened new Utah Medical Products positions in Q1 2018 and 9 closed out, a net change of +3 holders.
- The largest Utah Medical Products buyer in Q1 2018 was Lazard Asset Management, an estimated $10.1M added.
- The largest Utah Medical Products seller in Q1 2018 was Vanguard Group, an estimated $3.15M sold.
Based on aggregated 13F filings for Q1 2018.